Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis
Public ClinicalTrials.gov record NCT02045277. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of the study is to evaluate the safety and efficacy of a topical lotion
Study identification
- NCT ID
- NCT02045277
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 212 participants
Conditions and interventions
Conditions
Interventions
- IDP-118 Lotion Drug
- IDP-118 Monad HP Lotion Drug
- IDP-118 Monad Taz Lotion Drug
- IDP-118 Vehicle Lotion Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2014
- Primary completion
- Oct 31, 2014
- Completion
- Oct 31, 2014
- Last update posted
- Aug 19, 2020
2014
United States locations
- U.S. sites
- 18
- U.S. states
- 12
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Valeant Site 13 | Encino | California | 91436 | — |
| Valeant Site 11 | San Diego | California | 92123 | — |
| Valeant Site 15 | Santa Rosa | California | 95403 | — |
| Valeant Site 10 | Augusta | Georgia | 30909 | — |
| Valeant Site 09 | Newnan | Georgia | 30263 | — |
| Valeant Site 08 | Louisville | Kentucky | 40217 | — |
| Valeant Site 04 | Rockville | Maryland | 20850 | — |
| Valeant Site 14 | Clinton Township | Michigan | 48038 | — |
| Valeant Site 07 | Fridley | Minnesota | 55432 | — |
| Valeant Site 01 | East Windsor | New Jersey | 08520 | — |
| Valeant Site 03 | New York | New York | 10075 | — |
| Valeant Site 17 | Rochester | New York | 14623 | — |
| Valeant Site 02 | High Point | North Carolina | 27262 | — |
| Valeant Site 05 | Austin | Texas | 78759 | — |
| Valeant Site 06 | College Station | Texas | 77845 | — |
| Valeant Site 16 | Salt Lake City | Utah | 84117 | — |
| Valeant Site 18 | Lynchburg | Virginia | 24501 | — |
| Valeant Site 12 | Norfolk | Virginia | 23507 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Plaque Psoriasis trials
Other public records listing Plaque Psoriasis. Sorted by last update posted; newest first. Not a recommendation.
- NCT05739435: Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis Active, not recruiting
- NCT06220604: A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2) Active, not recruiting
- NCT06143878: A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis Active, not recruiting
- NCT07090330: ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis Active, not recruiting
- NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis Active, not recruiting
- NCT07250802: A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02045277, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 19, 2020 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02045277 live on ClinicalTrials.gov.